Bristol Myers ends Cellares manufacturing deal, signaling a possible pullback in cell therapy expansion.

What happened

Bristol Myers Squibb has terminated its partnership with Cellares, a startup focused on expanding manufacturing capacity for BMY's personalized blood cancer therapy, likely CAR-T drugs such as Breyanzi and Abecma. According to the DeepValue master report, BMY's cell therapy franchise shows mixed performance, with Breyanzi growing strongly (+49% in Q4'25) while Abecma declined (-4%), and the company is not highlighting cell therapy as a primary near-term growth driver. The termination likely reflects either sufficient existing capacity, a cost-reduction initiative, or a strategic reprioritization away from external manufacturing partnerships, consistent with management's focus on defending margins during the 2026 policy transition. This news does not alter the key scorecards for BMY's investment thesis—Eliquis growth and gross margin stability—but it does signal a potential scaling back of long-term cell therapy expansion ambitions. Overall, the event is minor in the context of BMY's larger challenges from IRA price resets and Revlimid erosion, and it should be monitored for signals on management's capital allocation priorities.

Implication

Investors should recognize that this move may indicate lower-than-expected demand for BMY's personalized cell therapies, particularly as Abecma continues to decline and competitive pressures mount. If BMY is scaling back manufacturing expansion, it could limit the upside from Breyanzi if demand accelerates, potentially creating a supply bottleneck. However, given that the company's near-term valuation hinges on Eliquis performance and gross margin defense, this news does not change the WAIT thesis, but it adds a modest negative for long-term growth optionality. The capital saved from ending this partnership could be redirected to higher-return pipeline investments or margin support, which would be viewed positively. Nonetheless, investors should watch for further signs that management is deprioritizing cell therapy investments, as that would reduce confidence in the Growth Portfolio's breadth.

Thesis delta

The termination of the Cellares partnership does not materially alter our WAIT thesis, which remains driven by Eliquis growth and gross margin stability through 2026. It introduces a minor negative for long-term cell therapy growth potential, but given the limited financial impact and lack of detail, we do not adjust our scenario probabilities or price targets. We maintain our focus on the upcoming quarterly scorecards for confirmation of the 2026 guidance.